A newly discovered gene that is essential for embryo survival could also hold the key to treating and potentially controlling chronic infections such as HIV, hepatitis and tuberculosis.
The gene, called Arih2, is fundamental to the function of the immune system – making critical decisions about whether to switch on the immune response to an infection.
Its discovery has implications for the treatment of chronic overwhelming infections, such as HIV, that 'exhaust' and switch off the immune system, as well as for chronic inflammatory (also known as autoimmune) conditions such as rheumatoid arthritis and sepsis.
Dr Marc Pellegrini, Dr Greg Ebert and colleagues from the institute's Infection and Immunity division, with collaborators from the University of Toronto, Canada, led the research. Their findings were published today in the journal Nature Immunology.
Infectious disease specialist and researcher Dr Pellegrini said that Arih2 is found in dendritic cells, the sentinels of the immune system that play an essential role in raising the alarm about the presence of foreign invaders in the body. "Arih2 is responsible for the most fundamental and important decision that the immune system has to make – whether the immune response should be initiated and progressed or whether it should be switched off to avoid the development of chronic inflammation or autoimmunity," Dr Pellegrini said. "If the wrong decision is made, the organism will either succumb to the infection, or succumb to autoimmunity."
Dr Pellegrini said although our immune system works well against many infections, some organisms have developed mechanisms to evade or counteract the immune system, allowing them to persist in the body. "During evolution, some organisms have evolved ways of exhausting our immune system to the point where the immune system just switches off, and this is what happens in HIV, hepatitis B and tuberculosis," he said. "These organisms counter the immune response – exhausting T cells which are stimulated over and over again by the infection and becoming exhausted or paralysed. With this current discovery, what we should be able to do is circumvent these mechanisms and reinvigorate the immune response temporarily to boost the immune system and help clear these infections."
Dr Ebert said the research team was now looking at the effect on the immune response of switching off Arih2 for short periods of time during chronic infections. "We are investigating how manipulating Arih2 and associated pathways promotes immunity in chronic overwhelming infections, where we know the immune response is inadequate," Dr Ebert said.
He said Arih2 had significant promise as a drug target. "Arih2 has a unique structure, which we believe make it an excellent target for a therapeutic drug, one that is unlikely to affect other proteins and cause unwanted side-effects," Dr Ebert said. "Because Arih2 is critical for survival, we now need to look at the effect of switching off the gene for short periods of time, to see if there is a window of opportunity for promoting the immune response to clear the infection without unwanted or collateral damage or autoimmunity."
Dr Pellegrini said it would take many years to translate the discovery to a drug that could be used in humans. "We are very excited about this discovery," Dr Pellegrini said. "Arih2 is the one of the most important genes involved in the most fundamental and vital decisions that the immune system has to make: whether or not to switch on the immune response to an infection. This discovery has significant implications for manipulating the immune response to infections and suppressing chronic inflammation or autoimmunity because we can target this gene to try to push immune responses in one or other direction – either promoting it or suppressing it," Dr Pellegrini said. "It is probably one of the few genes and pathways that is very targetable and could lead to a drug very quickly."
Walter and Eliza Hall Institute: http://www.wehi.edu.au/
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Slovenian archaeologist Ivan prajc is behind discovery of three significant ruins in the remote jungles of the Yucatán peninsula
Every year, Nikon selects the most artful, scientifically enlightening and skillfully produced images from thousands of submissions for its Small World microscope photography contest. Tomorrow, another set of impressive winners will be announced for the contest’s 40th year.
Seaview divers routinely cover 2 kilometers in a dive and generate 3,000 panoramic images in a day. Only a fraction of the best are uploaded to Google Street View.
Meeting sharks can be a moving experience, says photographer Jean-Marie Ghislain, who works to educate people on the plight of sharks around the world
From kraken to mermaids, some monsters are real—if you know how to look for them
Australia's Academy of Science says a government draft plan to protect the Great Barrier Reef will not prevent its decline.
France throbs like a beating heart as people converge on Paris from Monday to Friday, before heading out to the countryside at weekends, phone calls show
Experts estimate the mammoth was about 16 years old and lived about 70,000 to 120,000 years ago
Gladiators guzzled a drink made from plant ash to help their bodies recover after a hard day of sword fighting, according to Roman accounts. New tests of old bones back up that idea.
A veteran EMT and ambulance driver in Boston, Ed McCarthy is in a great position to understand his hometown spatially. But he’s also a history geek, and while constantly driving around the city’s neighborhoods, he loves recognizing the streets, buildings and other locales from the history books he so often buries his nose in.